Structural, functional and biochemical characterisation of apolipoprotein(a)-containing low-density lipoproteins.

J Colloid Interface Sci

Biofilm - Research Center for Biointerfaces and Department of Biomedical Science, Faculty of Health and Society, Malmö University, 20506 Malmö, Sweden; Instituto Biofisika (UPV/EHU, CSIC)) and Fundación Biofísica Bizkaia/Biofisika Bizkaia Fundazioa (FBB), University of the Basque Country, 48940

Published: August 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Atherosclerosis is the leading cause of cardiovascular diseases and remains a global health challenge. Low-density lipoproteins are crucial in atherogenesis, with plasma levels as significant independent predictors of the condition. Lipoprotein(a), Lp(a), is an LDL variant considered a stand-alone atherosclerosis predictor. Although structurally similar in composition to LDL, Lp(a) contains an additional protein, apolipoprotein(a), covalently linked to apolipoprotein-B100 via a disulfide bond. This distinguishing protein is believed to confer Lp(a) its distinctive properties, including marked heterogeneity. While many studies have structurally characterised LDL particles, Lp(a) remains understudied. In this study, we isolated LDL particles from serum of normolipidemic, healthy individuals with either low or high Lp(a) levels. Our study provides biochemical, structural and functional characterisation of low and high Lp(a)-total LDL fractions. Fourier transform infrared spectroscopy (FTIR) revealed that high Lp(a) LDL exhibited a reduced ability to remove lipids from model membranes compared to low Lp(a) LDL. However, this functional difference could not be sufficiently associated with structural differences in total LDL fractions, as determined by small-angle X-ray scattering (SAXS), except for a significant difference in the particles' core-to-shell scattering mass (SM) ratio. Western blot analysis further revealed a higher abundance of Lp(a) in a small-dense subfraction, LDL, leading us to hypothesise that structural differences might be more evident in these subfractions than in total fractions. Supporting this hypothesis, SAXS measurements on LDL subfractions from two subjects, with low and high Lp(a), revealed an increased protein shell thickness in high Lp(a) LDL, a feature not directly observed in total fractions. Our data thus suggests a key role of LDL in LDL dysfunction.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jcis.2025.138760DOI Listing

Publication Analysis

Top Keywords

lpa ldl
16
high lpa
16
ldl
13
low high
12
lpa
10
structural functional
8
low-density lipoproteins
8
ldl particles
8
ldl fractions
8
structural differences
8

Similar Publications

Lipoprotein(a) at a "Tipping Point": case to move to universal screening.

Am J Prev Cardiol

September 2025

Division of Cardiovascular Medicine, University of California San Diego, La Jolla, CA, USA.

Elevated lipoprotein(a) [Lp(a)] is well established as a common risk factor for atherosclerotic cardiovascular disease (ASCVD). Lp(a) levels are >90 % genetically determined. However, Lp(a) remains very underrecognized as a cardiovascular risk factor with low rates of testing.

View Article and Find Full Text PDF

Cardiovascular disease remains a major global health challenge, with dyslipidaemia being a key modifiable risk factor. While low density lipoprotein cholesterol (LDL-C) is the primary target for lipid-lowering therapies, recent evidence highlights the importance of triglycerides, apolipoprotein B (apoB), and lipoprotein(a) [Lp(a)] for residual cardiovascular risk. Current lipid-lowering therapies target key enzymes and proteins involved in cholesterol and lipid metabolism.

View Article and Find Full Text PDF

Background: The cholesteryl ester transfer protein inhibitor obicetrapib decreases levels of atherogenic lipids and raises high-density lipoprotein cholesterol (HDL-C).

Objectives: In this study, we sought to determine the effect of obicetrapib on cardiovascular events.

Methods: The effects of 10 mg obicetrapib and placebo daily on major adverse cardiovascular event (MACE) rates were investigated in a pooled analysis of 354 patients with heterozygous familial hypercholesterolemia (HeFH) and 2,530 patients with atherosclerotic cardiovascular disease (ASCVD) over 365 days.

View Article and Find Full Text PDF

Aims: Office-based cardiologists (OBCs) and general practitioners (GPs) follow different approaches for hypercholesterolemia management in atherosclerotic cardiovascular disease (ASCVD). This study evaluates whether differences in clinical practice between OBCs and GPs contribute to existing gaps in low-density lipoprotein cholesterol (LDL-C) control and lipoprotein(a) [Lp(a)] screening in ASCVD care.

Methods: LipidSnapshot is a collaborative research initiative comprising a prospective non-interventional study at OBCs and a retrospective analysis of GP records.

View Article and Find Full Text PDF

Antidepressants stimulate lipoprotein(a) macropinocytosis via serotonin-enhanced cell surface binding.

J Lipid Res

August 2025

Department of Biochemistry, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand; HeartOtago, University of Otago, Dunedin, New Zealand; Department of Molecular Medicine and EMBL Australia Node in Single Molecule Science, School of Biomedical Sciences, University of New South Wal

We recently found that plasminogen receptors regulate the plasma membrane binding and uptake of Lp(a) via macropinocytosis. In this study, we sought to further define lipoprotein(a) [Lp(a)] macropinocytosis, discovering an unexpected role for antidepressants and serotonin in the regulation of this process. We found that the tricyclic antidepressant imipramine enhanced Lp(a) uptake, in contradiction of its published role as a macropinocytosis inhibitor.

View Article and Find Full Text PDF